

## In Vivo Star Anti-Mouse CD274 (PD-L1) Antibody

|                           |                          |
|---------------------------|--------------------------|
| <b>Catalog Number:</b>    | 507801, 507802, 507803   |
| <b>Size:</b>              | 1 mg, 5 mg, 25 mg        |
| <b>Target Name:</b>       | PD-L1, PDL1 CD274, B7-H1 |
| <b>Regulatory Status:</b> | RUO                      |

### PRODUCT DETAILS

---

|                             |                                                                                                                         |
|-----------------------------|-------------------------------------------------------------------------------------------------------------------------|
| <b>Clone:</b>               | 10F.9G2                                                                                                                 |
| <b>Application:</b>         | ELISA, WB, Flow cytometry, IHC, ICC, animal model study                                                                 |
| <b>Reactivity:</b>          | Mouse                                                                                                                   |
| <b>Format:</b>              | Liquid                                                                                                                  |
| <b>Product Description:</b> | In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody                                                          |
| <b>Isotype:</b>             | Rat IgG2b Kappa                                                                                                         |
| <b>Antibody Type:</b>       | Recombinant                                                                                                             |
| <b>Purity:</b>              | >95% by reducing SDS-PAGE                                                                                               |
| <b>Endotoxin:</b>           | < 1 EU per 1 mg of the protein by the LAL method.                                                                       |
| <b>Storage Conditions:</b>  | 4°C                                                                                                                     |
| <b>Grade:</b>               | In vivo                                                                                                                 |
| <b>Recommended Usage:</b>   | This product is suitable for in vivo animal use. Optimal amounts need to be determined empirically for each experiment. |
| <b>Hidden Synonyms:</b>     | InVivoMab, InVivoPlus, GoInVivo, In Vivo Gold, 10F.9G2.1                                                                |

### BACKGROUND INFORMATION

---

Programmed death-ligand 1 (PD-L1), also known as CD274 or B7-H1, is a transmembrane protein that plays a pivotal role in immune regulation by modulating T cell activity. PD-L1 is expressed on a wide range of cells, including antigen-presenting cells, epithelial cells, and many tumor cells. Its primary function is to bind to its receptor, programmed cell death protein 1 (PD-1), located on activated T cells. This interaction delivers an inhibitory signal that reduces T cell proliferation, cytokine production, and cytotoxicity, thereby maintaining immune homeostasis and preventing autoimmunity. However, in pathological contexts such as cancer, PD-L1 expression allows tumor cells to evade immune attack, creating an immunosuppressive microenvironment.

Structurally, PD-L1 is a type I transmembrane glycoprotein belonging to the B7 family of immune checkpoint molecules. The extracellular domain comprises two immunoglobulin-like regions—an IgV-like domain responsible for PD-1 binding and an IgC-like domain that stabilizes the molecule. The protein also contains a single transmembrane helix and a short cytoplasmic tail that lacks classical signaling motifs but may interact with intracellular partners influencing its stability and localization. The PD-L1-PD-1 complex adopts a well-characterized interface where the IgV domains of both molecules interact in a way that blocks T cell

receptor-mediated activation signaling.

The main ligands of PD-L1 are PD-1 and CD80 (B7-1). While PD-1 engagement results in T cell inhibition, interaction with CD80 may yield bidirectional signaling effects depending on the cellular context. PD-L1 can be induced by inflammatory cytokines such as interferon-gamma (IFN- $\gamma$ ), linking innate immune responses to immune checkpoint modulation.

PD-L1 plays a major role in numerous diseases. Overexpression of PD-L1 is a hallmark of many cancers, including lung, melanoma, renal, and breast cancers, where it contributes to immune escape. Therapeutically, blocking the PD-1/PD-L1 axis with immune checkpoint inhibitors has revolutionized cancer treatment. Drugs such as pembrolizumab, nivolumab, and atezolizumab disrupt this inhibitory pathway, restoring antitumor T cell function. Moreover, PD-L1 is being explored as both a predictive biomarker for immunotherapy response and a target for novel therapies, including bispecific antibodies and CAR-T cells aimed at enhancing immune-mediated tumor clearance.

This product is supplied subject to the terms and conditions at [www.innocyto.com/web/terms.php](http://www.innocyto.com/web/terms.php) and may only be used as provided in the stated terms. Products are for Research Use Only.